{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-113589","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.729068+00:00","generated_at":"2026-06-09T00:52:07.069474+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organon Q3 revenue $1.52B, adj. EPS $0.87; narrows & lowers FY2023 guidance","bullets":["Revenue $1,519M (-1% YoY); diluted EPS $0.23; non-GAAP adj. diluted EPS $0.87.","Women's Health -7% ex-FX; Biosimilars +10% ex-FX; Established Brands +3% ex-FX.","Board declares quarterly dividend $0.28 per share, unchanged.","FY2023 revenue guidance narrowed to $6.15-6.25B (prev. $6.15-6.35B); adj. EBITDA margin 30.5-31.5% (prev. 31-33%).","Adjusted EBITDA $447M, margin 29.4% vs 35.5% a year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-113589","json":"https://secwatch.observer/filing/0001104659-23-113589.json","markdown":"https://secwatch.observer/filing/0001104659-23-113589.md","text":"https://secwatch.observer/filing/0001104659-23-113589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923113589/0001104659-23-113589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923113589/tm2329655d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:52:07.069474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0459db68987ccc8f2968011d235157452e9a30dd","claim":"Organon & Co. reported third quarter ended September 30, 2023 results: revenue $1,519 million, net income $58 million, EPS $0.23. Guidance lowered.","evidence_excerpt":"Organon Reports Results for the Third Quarter Ended September 30, 2023 • Third quarter 2023 revenue of $1,519 million • Third quarter 2023 diluted earnings per share of $0.23","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923113589/0001104659-23-113589-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$1,519 million"},{"label":"Net income","value":"$58 million"},{"label":"EPS","value":"$0.23"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}